# Topical Agents: Immunomodulators

**LENGTH OF AUTHORIZATIONS**: 365 Days

**STEP THERAPY:**

1.  For a product requiring step therapy, there must have been an inadequate clinical response to no less than two 30-day trials of topical corticosteroids
2.  For a non-preferred medication, there must have been inadequate clinical response to preferred alternatives, including a trial of no less than 30 days of the preferred medication

**OTHER APPROVAL CRITERIA:**

Is there any reason the patient cannot be changed to a medication not requiring prior approval?

Acceptable reasons include:

 Allergy to medications not requiring prior approval

 Contraindication to or drug interaction with medications not requiring prior approval

 History of unacceptable/toxic side effects to medications not requiring prior approval

**CLINICAL INFORMATION**

 Indicated for short-term and intermittent long-term treatment of atopic dermatitis if:

-   Alternative, conventional therapies (such as topical corticosteroids) are deemed inadvisable because of potential risks, or
    -   There has been inadequate response or intolerance to alternative, conventional therapies (such as topical corticosteroids)

         Elidel and Protopic 0.03% are indicated in patients 2 years old or older. Protopic 0.1% is indicated in adults only.

         Opzelura is contraindicated for use in immunocompromised patients

        AR - pimecrolimus and tacrolimus: a PA is required for patients younger than 2 years old
